Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2775 Target Snapshot

Transient receptor potential cation channel subfamily V member 4 · SINGLE PROTEIN · Rattus norvegicus

110Compounds
32Assays
2Approved Drugs
127.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt Q9ERZ8. Use UniProt Q9ERZ8 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9ERZ8 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Transient receptor potential cation channel subfamily V member 4 as ChEMBL target CHEMBL2775, mapped to UniProt Q9ERZ8. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Transient receptor potential cation channel subfamily V member 4
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-14
ChEMBL target ID
CHEMBL2775
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9ERZ8
Transient receptor potential cation channel subfamily V member 4
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Transient receptor potential cation channel subfamily V member 4 is the right protein anchor across sources, using UniProt Q9ERZ8 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTransient receptor potential cation channel subfamily V member 4
UniProt AccessionQ9ERZ8
Component TypeProtein
Sequence Length871 aa

Transient receptor potential cation channel subfamily V member 4

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Transient receptor potential cation channel subfamily V member 4, mapped to UniProt Q9ERZ8. Sequence length is 871 aa.

Mapped IDQ9ERZ8
Review nameTransient receptor potential cation channel subfamily V member 4
OrganismRattus norvegicus
Clinical Profile

Clinical Phase Distribution

2
Approved
1
Phase III
1
Phase II
Assay Mix

Activity Type Distribution

IC50114.0
EC5013.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4578182 9.49 IC50 0.32 Preclinical
CHEMBL4465116 9.14 IC50 0.73 Preclinical
CHEMBL4461475 9.0 IC50 1.0 Preclinical
CHEMBL4459940 8.96 IC50 1.1 Preclinical
CHEMBL4104743 8.8 IC50 1.6 Preclinical
CHEMBL4470585 8.8 IC50 1.6 Clinical
CHEMBL4073922 8.7 IC50 2.0 Preclinical
CHEMBL3941914 8.68 IC50 2.1 Preclinical
CHEMBL4084542 8.6 IC50 2.5 Preclinical
CHEMBL4087716 8.6 IC50 2.5 Preclinical
Distribution

pChEMBL Value Distribution

10
5.0
8
5.5
16
6.0
12
6.5
13
7.0
11
7.5
14
8.0
10
8.5
3
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

CANNABIDIOL
CHEMBL190461
Approved 2018
Assay Landscape

Assay Landscape

32
Total Assays
98
Tested Compounds
1
Assay Types
Binding — 32 assays, 98 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 27 76 6.9
single protein format 5 22 7.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine